Update on poly(ADP-ribose) polymerase inhibitors resistance in ovarian cancer

Ruihong Dong; Ruihong Dong; Ting Ding; Ting Ding; Zhengyu Li; Zhengyu Li

doi:10.3389/fphar.2023.1164395

Frontiers in Pharmacology (Jun 2023)

Update on poly(ADP-ribose) polymerase inhibitors resistance in ovarian cancer

Ruihong Dong,
Ruihong Dong,
Ting Ding,
Ting Ding,
Zhengyu Li,
Zhengyu Li

Affiliations

Ruihong Dong: Department of Gynecology and Obstetrics, West China Second University Hospital, Sichuan University, Chengdu, China
Ruihong Dong: Key Laboratory of Birth Defects and Related Diseases of Women and Children (Sichuan University), Ministry of Education, Chengdu, China
Ting Ding: Department of Gynecology and Obstetrics, West China Second University Hospital, Sichuan University, Chengdu, China
Ting Ding: Key Laboratory of Birth Defects and Related Diseases of Women and Children (Sichuan University), Ministry of Education, Chengdu, China
Zhengyu Li: Department of Gynecology and Obstetrics, West China Second University Hospital, Sichuan University, Chengdu, China
Zhengyu Li: Key Laboratory of Birth Defects and Related Diseases of Women and Children (Sichuan University), Ministry of Education, Chengdu, China

DOI: https://doi.org/10.3389/fphar.2023.1164395
Journal volume & issue: Vol. 14

Abstract

Read online

Ovarian cancer is one of the most common reproductive system tumors. The incidence of ovarian cancer in China is on the rise. Poly(ADP-ribose) polymerase (PARP) inhibitor (PARPi) is a DNA repair enzyme associated with DNA damage repair. PARPi takes PARP as a target to kill tumor cells, especially for tumors with homologous recombination (HR) dysfunction. Currently, PARPi has been widely used in clinical practice, mainly for the maintenance of advanced ovarian epithelial cancer. The intrinsic or acquired drug resistance of PARPi has gradually become an important clinical problem with the wide application of PARPi. This review summarizes the mechanisms of PARPi resistance and the current progress on PARPi-based combination strategies.

Published in Frontiers in Pharmacology

ISSN: 1663-9812 (Online)
Publisher: Frontiers Media S.A.
Country of publisher: Switzerland
LCC subjects: Medicine: Therapeutics. Pharmacology
Website: http://journal.frontiersin.org/journals/pharmacology

About the journal

Abstract

Keywords